Research programme: cancer and HIV biotherapies - InnaVirVaxAlternative Names: IVV001; STOP3S
Latest Information Update: 16 Jul 2016
At a glance
- Originator InnaVirVax
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in France
- 16 Jul 2016 No recent reports of development identified for research development in HIV-infections in France
- 16 Jul 2010 Early research in HIV infections in France (unspecified route)